Biomedical Engineering Reference
In-Depth Information
175. Talon S, De Luca A, De Bellis M, Desaphy J-F, Lentini G, Scilimati A, Corbo F, Franchini C,
Tortorella P, Jockusch H, Conte Camerino D (2001) Increased rigidity of the chiral centre of
tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na
+
channels
enhancing the antimyotonic activity in vivo. Br J Pharmacol 134:1523-1531
176. De Luca A, Talon S, De Bellis M, Desaphy J-F, Lentini G, Corbo F, Scilimati A, Franchini C,
Tortorella P (2003) Optimal requirements for high affinity and use-dependent block of
skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds. Mol
Pharmacol 64:932-945
177. De Bellis M, De Luca A, Lentini G, Carocci A, Corbo F, Franchini C, Conte Camerino D
(2009) Newly synthesized mexiletine and tocainide analogues are potent use-dependent
blockers of skeletal muscle sodium channels: potential implication for the antimyotonic
activity. Neuromuscul Disord. doi:10.1016/j.nmd.2009.06.318
178. Le Grand B, Pignier C, L
´
tienne R, Cuisiat F, Rolland F, Mas A, Vacher B (2008) Sodium
late current blockers in ischemia reperfusion:
is the bullet magic? J Med Chem
51:3856-3866
179. Saint DA (2008) The cardiac persistent sodium current: an appealing therapeutic target? Br J
Pharmacol 153:1133-1142
180. Tamareille S, Le Grand B, John GW, Feuvray D, Coulombe A (2002) Anti-ischemic
compound KC12291 prevents diastolic contracture in isolated atria by blockade of volt-
age-gated sodium channels. J Cardiovasc Pharmacol 40:346-355
181. John GW, L´tienne R, Le Grand B, Pignier C, Vacher B, Patoiseau J-F, Colpaert FC,
Coulombe A (2004) KC 12291: an atypical sodium channel blocker with myocardial
antiischemic properties. Cardiovasc Drug Rev 22:17-26
182. Hayashida W, van Eyll C, Rousseau MF, Pouleur H (1994) Effects of ranolazine on left
ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc
Drugs Ther 8:741-747
183. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W,
Nelson JJ, Hebert DA, Wolff AA (2004) Anti-ischemic effects and long-term survival during
ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol
43:1375-1382
184. Belardinelli L, Shryock JC, Fraser H (2006) The mechanism of ranolazine action to reduce
ischemia-induced diastolic dysfunction. Eur Heart J Suppl 8:A10-A13
185. Song Y, Shryock JC, Wu L, Belardinelli L (2004) Antagonism by ranolazine of the pro-
arrhythmic effects of increasing I
Na
in guinea pig ventricular myocytes. J Cardiovasc
Pharmacol 44:192-199
186. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM,
Cordeiro JM, Thomas G (2004) Electrophysiological effects of ranolazine, a novel
antianginal agent with antiarrhythmic properties. Circulation 110:904-910
187. Hale SL, Kloner RA (2006) Ranolazine, an inhibitor of the late sodium channel current,
reduces postischemic myocardial dysfunction in the rabbit. J Cardiovasc Pharmacol Ther
11:249-255
188. Vi
´
B, Sablayrolles S, L
`
tienne R, Vacher B, Darmellah MB, Feuvray D, Le Grand B (2009)
3-(R)-[3-(2-methoxyphenylthio-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-
benzoxathiepine bromhydrate (F 15845) prevents ischemia-induced heart remodeling by
reduction of the intracellular Na
+
overload. J Pharm Exp Ther 330:696-703
189. Vacher B, Pignier C, L`tienne R, Verscheure Y, Le Grand B (2009) F 15845 inhibits
persistent sodium current in the heart and prevents angina in animal models. Br J Pharmacol
156:214-225
190. Finnin M (2010) Vernakalant: a novel agent for the termination of atrial fibrillation. Am J
Health Syst Pharm 67:1157-1164
191. Orth PMR, Hesketh JC, Mak CKH, Yang Y, Lin S, Beatch GN, Ezrin AM, Fedida D (2006)
RSD1235 blocks late I
Na
and suppresses early afterdepolarizations and torsade de pointes
induced by class III agents. Cardiovasc Res 70:486-496
